{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:11:15Z","timestamp":1790683875773,"version":"4.1.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,3]]},"DOI":"10.7759\/cureus.75057","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T01:23:37Z","timestamp":1733275417000},"source":"Crossref","is-referenced-by-count":2,"title":["Management and Treatment of Primary Membranous Nephropathy With a Positive PLA2R Marker"],"prefix":"10.7759","author":[{"given":"Rajesh","family":"Metuku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin B","family":"Wynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.07.006","article-title":"AJKD atlas of renal pathology: membranous nephropathy","volume":"66","author":"Fogo AB","year":"2015","unstructured":"Fogo AB, Lusco MA, Najafian B, Alpers CE. AJKD atlas of renal pathology: membranous nephropathy. Am J Kidney Dis. 2015, 66:e15-7. 10.1053\/j.ajkd.2015.07.006","journal-title":"Am J Kidney Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck LH Jr","year":"2009","unstructured":"Beck LH Jr, Bonegio RG, Lambeau G, et al.. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009, 361:11-21. 10.1056\/NEJMoa0810457","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014111061","article-title":"Epitope spreading of autoantibody response to pla2r associates with poor prognosis in membranous nephropathy","volume":"27","author":"Seitz-Polski B","year":"2016","unstructured":"Seitz-Polski B, Dolla G, Payr\u00e9 C, et al.. Epitope spreading of autoantibody response to pla2r associates with poor prognosis in membranous nephropathy. J Am Soc Nephrol. 2016, 27:1517-33. 10.1681\/ASN.2014111061","journal-title":"J Am Soc Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1159\/000437236","article-title":"Anti-PLA2R antibodies as a prognostic factor in PLA2R-related membranous nephropathy","volume":"42","author":"Timmermans SA","year":"2015","unstructured":"Timmermans SA, Abdul Hamid MA, Cohen Tervaert JW, Damoiseaux JG, van Paassen P. Anti-PLA2R antibodies as a prognostic factor in PLA2R-related membranous nephropathy. Am J Nephrol. 2015, 42:70-7. 10.1159\/000437236","journal-title":"Am J Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07210810","article-title":"Anti-phospholipase A\u2082 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy","volume":"6","author":"Hofstra JM","year":"2011","unstructured":"Hofstra JM, Beck LH Jr, Beck DM, Wetzels JF, Salant DJ. Anti-phospholipase A\u2082 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2011, 6:1286-91. 10.2215\/CJN.07210810","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016070776","article-title":"A proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese AS","year":"2017","unstructured":"De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC. A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol. 2017, 28:421-30. 10.1681\/ASN.2016070776","journal-title":"J Am Soc Nephrol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza FC","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ, et al.. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019, 381:36-46. 10.1056\/NEJMoa1814427","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007020166","article-title":"A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy","volume":"18","author":"Jha V","year":"2007","unstructured":"Jha V, Ganguli A, Saha TK, et al.. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol. 2007, 18:1899-904. 10.1681\/ASN.2007020166","journal-title":"J Am Soc Nephrol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/282806-management-and-treatment-of-primary-membranous-nephropathy-with-a-positive-pla2r-marker","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T01:23:38Z","timestamp":1733275418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/282806-management-and-treatment-of-primary-membranous-nephropathy-with-a-positive-pla2r-marker"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.75057","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,3]]}}}